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Abstract. Metabolic aberrations in diabetes such as hyperglycemia, ketonemia, ketonuria, 
reduced glycogen in tissues and reduced rates of fatty acid synthesis in the liver are 
corrected by the administration of lipoic acid. Dithiol octanoic acid is formed from lipoic 
acid by reduction and substitutes for Coenzyme A in several enzymatic reactions such as 
pyruvate dehydrogenase, citrate synthase, acetyl Coenzyme A carboxylase, fatty acid 
synthetase, and triglyceride and phospholipid biosynthesis; but not in the oxidation of fatty 
acids because of the slow rates of thiolysis of ß-keto acyl dithioloctanoic acid. The overall 
effect of these changes in the key enzymic activities is seen in the increased rates of oxidation 
of glucose and a reduction in fatty acid oxidation in diabetes following lipoic acid admini-
stration. 
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Introduction 
 
Diabetes is a disease that affects a significant proportion of the population and is 
characterised by abnormal carbohydrate, fat and protein metabolisms. There are two 
types of diabetes: type I (juvenile diabetes) and type II (maturity onset diabetes). 
Type I diabetes, is characterised by low levels of serum insulin and these patients 
have an absolute requirement for insulin. On the other hand, type II diabetics have 
normal or supranormal levels of serum insulin and are often obese (Chiles and 
Tzagournis, 1970). The causes of type I diabetes are many including genetic predis-
position (Foster, 1983), overproduction of counter regulatory hormones such as 
glucagon, growth hormone, etc. (Zadik et al., 1980) presence of insulinase and insulin 
antibodies (Neufeld et al., 1980). The causes of type II diabetes have been attributed 
to a reduction in hormone receptor levels on target cells and impairment of 'post-
receptor' functions (Olefsky and Kotterman, 1981). 
The major biochemical abnormalities in diabetes are increased blood sugar 
(hyperglycemia) decreased glucose tolerance, urinary sugar (glucosuria), increased 
serum pyruvate, lactate, acetoacetate and triglycerides, reduced glycogen in the 
tissues, impaired fat biosynthesis in the liver and increased gluconeogenesis in the 
liver and kidney. 
In earlier studies from this laboratory, we have shown that lipoic acid or dithio- 
loctanoic acid (DTO) administration in alloxan diabetic rats brings about significant 
reductions in blood sugar, serum pyruvate and acetoacetate levels and increases in 
liver glycogen and fat synthesis (Natraj et al., 1984; Gandhi et al., 1985). Further, 
relative α-lipoic acid content of alloxan diabetic rat livers was considerably less than 
 
 
Abbreviations used: DTO, Dithioloctanic acid; CoA, Coenzyme A; acetyl DTO, acetyl dihydrolipoic acid; 
DTNB, 5,5-dithiobis (2-nitrobenzoic acid); TLC, thin-layer chromatography; HMG, hydroxy methyl 
glutanic acid. 
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that of normal livers. Intraperitoneal administration of lipoic acid (10 mg/ 100 g) did 
not effect changes in serum insulin levels in normal and alloxan diabetic rats, while 
normalising increased serum pyruvate and impaired liver pyruvate dehydrogenase 
(EC 1·2·4·1) characteristic of the diabetic state (Gandhi et al., 1985). 
The metabolic disposition of pyruvate occurs by 3 pathways: (i) production of 
lactate through lactate dehydrogenase (EC 1·1·1·27)—lactic acidemia is a charac-
teristic of uncontrolled diabetes; (ii) conversion of pyruvate by carboxylation to 
oxalacetate—pyruvate carboxylation is increased in diabetes in an effort to produce 
glucose by gluconeogenesis and (iii) decarboxylation to acetyl Coenzyme A (CoA) 
and CO2. High production of acetyl CoA through fatty acid oxidation is known to 
inhibit pyruvate dehydrogenase and also to stimulate pyruvate carboxylase 
(EC 6·4·1·1). We found that acetyl DTO does not stimulate pyruvate carboxylase and 
DTO in fact activates pyruvate dehydrogenase. 
Whereas DTO can substitute for CoA in a variety of enzymic reactions (vide infra), 
β-keto fatty acyl lipoate is sparsely thiolyzed to yield acetyl dihydrolipoic acid (ace- 
tyl DTO). The reduced thiolysis of β-keto fatty acyl DTO and the lack of activation 
of pyruvate carboxylase by acetyl DTO could account for the antiketotic and anti-
gluconeogenic effects of lipoic acid. The metabolic role of lipoic acid as evidenced by 
its participation in a number of enzymatic reactions involved in carbohydrate and 
lipid metabolism will be discussed in this paper with a view to focus attention on the 
significance of DTO in general metabolism as well as its specific role in the treatment 
of diabetes. 
 
Pyruvate dehydrogenase 
 
Lipoic acid is a cofactor in the multienzyme complexes of α-keto acid dehydrogena-
ses such as pyruvate, α-keto glutarate and branched chain α-keto acid dehydroge-
nases. Pyruvate is a metabolite located at the nexus of the 3 metabolisms affected in 
diabetes, viz., carbohydrate, fat and protein metabolisms. We had shown earlier that 
lipoid acid levels are reduced in diabetes and administration of lipoic acid stimulates 
pyruvate dehydrogenase (Gandhi et al., 1985). It is probable therefore that some of 
the effects of lipoic acid such as reduction in serum pyruvate and part of the blood 
sugar reduction could be explained through increased rates of utilization of pyruvate 
and therefore glucose for energy generation and for anabolic reactions. In this 
connection, it must be mentioned that administration of dichloroacetate which also 
stimulates pyruvate dehydrogenase, lowers serum pyruvate and blood sugar in dia-
betic rats (Whitehouse and Randle, 1973). 
Although dichloroacetate and lipoic acid stimulate pyruvate dehydrogenase and 
bring about reductions in serum pyruvate and blood sugar levels, they difer in at 
least one crucial respect, i.e., while lipoic acid brings down serum acetoacetate levels 
(Natraj et al., 1984) dichloroacetate administration does not (Stackpoole et al., 1978; 
Gerard et al., 1979). It is reasonable to conclude that stimulation of pyruvate 
dehydrogenase alone cannot explain all the observed effects of lipoid acid in diabetes 
and any proposal for the mode of action of lipoid acid must explain the reduction in 
ketosis. 
The role of lipoic acid as a carrier of acetyl groups and electrons between pyruvate 
and CoA in the enzyme complex of pyruvate dehydrogenase has been well establi- 
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shed. The activity of the enzyme is regulated by reversible phosphorylation (inactive) 
and dephosphorylation (active) catalyzed by two specific enzymes pyruvate dehydro-
genase kinase and pyruvate dehydrogenase phosphatase, respectively (Kerbey et al., 
1976). In streptozotocin diabetic rats, it has been shown that the fraction of the 
enzyme in the active form is reduced, while the total amount of the enzyme is not 
changed (Weinberg and Utter, 1980). 
Apart of the loss in enzyme activity in diabetes could be due to the reduction in 
lipoic acid substitution at the enzyme level. However, this does not explain the 
stimulation of pyruvate dehydrogenase following lipoic acid administration in normal 
rats where lipoic acid substitution is presumed to be optimal. 
In order to explain this, it is necessary to take a closer look at the effects of the 
product, acetyl CoA on the enzyme activity. 
Wieland et al. (1971) have shown that in the presence of acetyl CoA, the enzyme 
undergoes inactivation. The mechanism of this inactivation has been shown to be 
through stimulation of the kinase (Cate and Roche, 1983). Dichloroacetate inhibits 
pyruvate dehydrogenase kinase thus stimulating pyruvate dehydrogenase. 
In diabetes, as is well known, increased oxidation of fatty acids occurs. As a result, 
acetyl CoA accumulates in the liver mitochondria. The observed increase in the 
proportion of the inactive form of pyruvate dehydrogenase could be a direct con-
sequence of this. It has also been shown that this inactivation of the enzyme can be 
reversed by incubating the inactive enzyme with CoA (Cate and Roche, 1983). The 
question is whether DTO can substitute for CoA in this reaction. 
Pyruvate dehydrogenase isolated from normal rat liver mitochondria has been 
assayed with DTO in the complete absence of CoA, and for the first time, it has been 
shown that pyruvate can be converted to acetyl DTO (Gandhi et al., 1985). It is 
therefore probable that in the diabetic liver when the enzyme is inactivated due to 
acylation of the enzyme bound lipoic acid, DTO could help overcome the inhibition 
by deacylating the enzyme. The same argument can be extended to normal rat liver 
pyruvate dehydrogenase where it is probable that a certain proportion of the enzyme 
exists in the catalytically inactive form due to acylation of enzyme bound lipoic acid. 
Lipoic acid administration in diabetes therefore affects pyruvate dehydrogenase in 
two ways; activation by deacylating the enzyme bound acetyl groups and secondly, 
by reducing the rate of acetyl CoA production by inhibiting fatty acid oxidation. 
 
 
Pyruvate carboxylase 
 
Pyruvate carboxylase catalyzes and initiates gluconeogenesis from pyruvate and 
alanine (Utter et al., 1964). It is an allosteric enzyme and from different sources, it has 
been shown that it has an absolute requirement for acetyl CoA for maximum 
activity. The activity and the number of copies of this enzyme have been shown to be 
increased in streptozotocin diabetes (Weinberg and Utter, 1980). Increased gluco-
neogenesis contributes to the hyperglycemic conditon in diabetes. 
Pyruvate carboxylase has been isolated from normal rat liver mitochondria and 
assayed by coupling with excess citrate synthase (EC 4·1·3·7). The overall reaction is 
the conversion of pyruvate in the presence of acetyl CoA or acetyl DTO to oxal-
acetate followed by the condensation of oxalacetate with acetyl CoA or acetyl DTO 
to citrate. The formation of citrate was monitored by measuring the free thiol relea- 
62 Wagh et al. 
 
sed from acetyl CoA or acetyl DTO using 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) 
and also by estimating citrate colourimetrically. The specific activity of the enzyme 
with acetyl CoA as the modulator was 43·82 n mol of citrate formed/min/mg protein, 
whereas with acetyl DTO no citrate could be detected indicating that acetyl DTO 
does not stimulate oxalacetate formation from pyruvate (Gandhi et al., 1985). Lipoic 
acid administered to diabetic animals can get converted to acetyl DTO, which does 
not stimulate gluconeogenesis, thus contributing to a reduction in blood sugar levels. 
 
 
DTO in fatty acid, triglyceride and phospholipid synthesis 
 
We have demonstrated for the first time that DTO can participate in the acetate 
activation step to form acetyl DTO which can be carboxylated to malonyl DTO with 
subsequent formation of palmitate in the same way as CoA does in fatty acid bio-
synthesis (Wagh et al., 1986). Acetyl CoA synthetase (EC 6·2·1·1) was isolated from 
rat liver mitochondria and the assay was carried out in the presence of ATP and 
CoA or DTO. Acetyl CoA or acetyl DTO formation was monitored by the hy-
droxamate assay (Jones and Lipmann, 1955). The specific activity of the enzyme with 
CoA was 1·61 and with DTO 0·78 µ mol of product formed/min/mg protein. DTO 
was approximately half as effective as CoA in this reaction. 
Apart from acetate activation, DTO is also effective in the activation of fatty acids 
to fatty acyl DTO. Batty acyl CoA synthetase (EC 6·2·1·3) was isolated from normal 
rat liver microsomes. The reaction was monitored by taking [l-14C]-palmitic acid 
and incubating with CoA or DTO in the presence of enzyme and ATP. The product 
was extracted, separated on thin-layer chromatography (TLC) and the radioactivity 
incorporated into fatty acyl CoA or fatty acyl DTO was measured. The specific 
activity with CoA was found to be 32 and with DTO 44 µ mol DTO 
acylated/min/mg protein. In this reaction, DTO was found to be comparable to CoA 
(Gandhi et al., 1985). 
On the other hand, the specific activity of acetyl DTO in the carboxylation to 
malonyl DTO is only about 60% of that of acetyl CoA to malonyl CoA (Gandhi et 
al., 1985) (table 1). 
 
Table 1. Acetyl CoA carboxylase. 
AcCoA (DTO)+ NaH14 Co3+ 
ATP → Mal CoA (DTO) 
 
*nmolofCO2fixed/min/mg protein. 
Acetyl CoA carboxylase was isolated from rat liver 
cytosol and partially purified. The incorporation of 
[14C] -NaHCO3 into acid stable counts was used to 
assay the enzyme. The product was identified as 
malonyl DTO. 
 
Similarly, acetyl DTO is only about half as effective as acetyl CoA in the fatty acid 
synthetase system from normal rat liver cytosol (table 2). 
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Table 2. Fatty acid synthetase. 
 
8 AcCoA(DTO)+ 14 NADPH+ 7 ATP+ 
7HCO −
3
+ 14Η+ →Palmitate + 8 CoA (DTO) + 7 ADP + 
7Pi + 14 NADP++6H2O 
 
Fatty acid synthetase was isolated from normal rat livers (Stoops et al., 
1979) and the activity estimated by coupling with acetyl CoA carboxy-
lase and determining the rate of oxidation of NADPH measured 
spectrophotometrically or the radioactivity incorporated from [1-14C]- 
acetyl CoA or [l-14C]-acety1 DTO into palmitate which was isolated 
from the reaction mixture and purified by TLC. Numbers in paren-
theses are the n mol of palmitate produced/min/mg protein. 
 
In nature, fatty acids are converted either to triglycerides or phospholipids. Figure 
1 gives a skeletal view of the biosynthesis of triglycerides and some of the phosphor-
lipids. Sn-3-glycerol phosphate formed from dihydroxy acetone phosphate is usually 
acylated by a saturated fatty acyl CoA in the α-position and subsequently by an 
unsaturated fatty acyl CoA in the ß-position to yield phosphatidic acid, Phosphatidic 
acid is converted to phosphatidyl serine, phosphatidyl inositol or cardiolipin by a 
series of steps involving cytidine triphosphate. Through the action of a phosphatase, 
phosphatidic acid is converted to α-β-diglyceride which is the substrate for the 
formation of either triglycerides or phosphatidyl choline (lecithin) or phosphatidyl 
ethanolamine (cephalin). We have examined whether triglyceride and phospholipid 
biosynthesis could take place with DTO esters of saturated and unsaturated fatty 
acids in the same way CoA esters do using rat liver microsomes (table 3). 
These experiments were conducted using [U–14C]-labelled glycerol 3 phosphate 
and table 3 shows that the synthesis of total lipids occurs, in fact better with 
palmitoyl + oleyl DTO than that with palmitoyl + oleyl CoA. This increase in lipid 
synthesis using fatty acyl DTO is reflected not so much in neutral lipid synthesis but 
more in the synthesis of phosphatidic acid and more particularly in the synthesis of 
phosphatidyl choline (lecithin). 
 
DTO, fatty acid oxidation and acetoacetate metabolism 
 
It is now well established that ketosis occurs primarily due to increased oxidation of 
fats in diabetes (Ohgaku et al., 1983). Therefore, the effects of lipoic acid administra-
tion on fatty acid and glucose oxidation in normal and diabetic rats was investigated. 
Having shown that DTO substitutes for CoA in the biosynthesis of fatty acids, 
triglycerides as well as phospholipids with more or less equal facility, we were 
interested in examining more closely the various steps in fatty acid oxidation with a 
view to see whether DTO participates in fatty acid oxidation as well. As shown in 
figure 2, acetoacetyl CoA is the pivotal product formed from fatty acid oxidation. 
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Figure 1. Trigiyceride and phospholipid biosynthesis. 
 
Acetoacetyl CoA can form acetoacetate either by deacylation (Segal and Menon, 
1961) or by cleavage from hydroxy methyl glutaryl (HMG) CoA (Sauer and Erfle 
1966). Further, acetoacetate can also be formed from acetoacetyl CoA by the thio– 
phorase (EC 2·8·3·5) reaction involving succinyl, malonyl and other dicarboxylic 
substrates (Hersh and Jencks, 1967; Moore and Jencks, 1982). Acetoacetyl CoA is 
biosynthesised through the reversal of the thiolase (EC 2·3·1·9) reaction, i.e., from two 
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Table 3. Triglyceride and phospholipid biosynthesis in isolated rat 
liver microsomes. 
 
All values are means of 5 independent determinations. 
b Significancy higher than a Ρ <·0·01. 
d Significantly higher than c Ρ < 0·001. 
Rat liver microsomes were isolated according to Yamashita and Numa 
(1981). Incorporation of [U-14C]-Sn-glycerol-3-phosphate into 
triglyceride and phospholipids in rat liver microsomes was carried out 
according to Schneider (1963). The assay mixture in a final volume of 
0·4ml contained 1·2 m mol of Tris-HCl buffer pH 8·0, 0·1 µmol 
phosphoryl choline 0·2 µmol CTP, 0·3 µmol ATP, 6 mg glycerol 1–2 µmol 
β–mercaptoethanol, phosphoryl choline cytidyl transferase (1 mg 
protein). The mixture was incubated for 30 min and 30 n mol of 
palmitoyl Co A and oleyl CoA or 30 n mol of palmitoyl DTO and 
31 n mol of oleyl DTO was added. The mixture was incubated for a 
further 30 min, extracted with chloroform methanol 2:1 v/v and the 
fractions of neutral and phospholipids separated by silicic acid column 
chromatography (Sweeley, 1969). The fractions were counted for radio-
activity. 
 
Figure 2. Formation and metabolism of acetoacetate. 
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molecules of acetyl CoA and also from the terminal 4 carbon atoms of a fatty acid 
molecule during fatty acid oxidation. 
Table 4 shows that DTO does not participate in the thiolase reaction, for example, 
there is no acetyl DTO formation from acetoacetyl DTO + DTO. On the other hand, 
DTO seems to participate albeit to a very small extent in the mixed thiolase reaction 
like acetoacetyl CoA + DTO or acetoacetyl DTO + CoA. These findings support the 
effect of DTO in reducing blood acetoacetate levels and point to its usefulness in the 
prevention of acidosis in diabetes. 
 
Table 4. Thiolysis of acetoacetyl DTO. 
AcAcCo'A+COA 2AcCoA 
 
 
Thiolase was partially purified from normal rat liver mito-
chondria. The enzyme was assayed by monitoring the decrease 
in A310 absorption which is an indication of the disappearance 
of acetoacetyl thioester. One unit of activity corresponds to a 
decrease in A310 of 0·01/min. 
*Not detectable. 
 
 
Table 5. Succinyl CoA: 3 oxo acid transferase. 
Succinyl, CoA+AcAc CoA+Succinate 
 
ND, Not detectable. 
The enzyme was isolated from rat hearts according to Stearn et al. (1956). The 
enzyme was assayed by monitoring the disappearance of acetoacetyl thioester, 
on addition of succinate, by the decrease in A310 absorbance. 
 
 
Further, as shown in table 5, acetoacetyl DTO does not lead to the formation of 
acetoacetate by the thiophorase reaction using succinate. Acetoacetyl DTO therefore 
does not contribute to ketone body formation via thiophorase reaction. Further, 
acetoacetyl DTO may have a feedback inhibition effect on fatty acid oxidation thus 
ensuring reduced catabolism of fat especially in conditions like diabetes. 
HMG.DTO is formed from acetoacetyl DTO and acetyl DTO to about half the 
level of HMG. CoA from acetoacetyl CoA and acetyl CoA (table 6). 
Another metabolic reaction of importance is the formation of dicarboxylate thio-esters. 
Succinyl CoA synthetase (EC 6·2·1·4) was isolated from rat hearts according to 
Murakami and Nishimura (1974). The assay was carried out by incubating succinate 
and  CoA or  DTO and fol lowing the increase in  absorbance at  235 nm 
spectrophotometrically. The activity with DTO was approximatly 40% of that with 
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Table 6. Formation of HMG.CoA/DTO catalyzed by HMG.CoA synthetase. 
 
ND, Not detectable. 
The enzymes were isolated from rat liver cytosol or mitochondrial fractions
according to Clinkenbeard et al. (1980). The assay mixture in a final volume of 1 ml 
contained 100 µ mol Tris HCl, 01 µ mol EDTA, 0·2 µ mol acetyl CoA or acetyl 
DTO, 0·05 µ mol acetoacetyl CoA or acetoacetyl DTO, 20 µmol MgCl2 and 200 µg 
enzyme protein. The disappearance of acetoacetyl CoA or acetoacetyl DTO was 
monitored spectrophotometrically at 310 nm. 
 
CoA. Succinyl CoA is also formed by the decarboxylation of α-keto glutarate even as 
acetyl CoA is formed by the oxidation of pyruvate. 
It may be worthwhile pointing out that in the thiolase reaction acetoacetyl DTO 
was ineffective. Burther, whereas in mixed thiolase reaction DTO evinced low acti-
vity levels, it had no effect at all in HMG formation. The summary of our 
investigation on acetoacetate metabolism is presented in figure 3. The length of the 
arrows represent the ratio of the activity of CoA and DTO derivatives. It will be seen 
from figure 3 that DTO reduces the formation of acetoacetyl DTO and HMG.DTO 
precursors for biosynthesis of cholesterol because of reduced thiolase activity and 
reduced thiophorase activity. On the other hand, the removal of ketosis, that is, con-
version of acetoacetate to acetoacetyl DTO is well performed by DTO. So taking the 
4 major reactions leading to ketogenesis and cholesterogenesis it may be stated on 
balance that DTO would help reduction of both. 
 
Effects of lipoic acid on [U-I4C] -glucose and [U-14C] -palmitic acid oxidation in intact 
rats 
 
The reactions of DTO and acetyl DTO in various enzyme systems subtly alters the 
overall utilization of carbohydrates and fat in diabetic rats. In order to establish this, 
the oxidation of [U-14C]-glucose and [l-14C]-palmitic acid in normal and diabetic 
rats following lipoid acid administration was measured. These results were compared 
with those obtained by the administration of insulin and glibenclamide (an oral 
hypoglycaemic drug). 
Tables 7 and 8 show the effect of intraperitoneal administration of lipoic acid and 
insulin and oral administration of glibenclamide on 14CO2 expiration from [U-14C]- 
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Figure 3. Acetoacelate metabolism. 
 
Table 7. 14CO2 expiration from [U-14C]-glucose. 
 
 
Numbers in parentheses indicate the number of animals. Lipoic acid 
(100 mg/kg) and insulin (40 i.u/kg) were administered intraperitoneally. 
Glibenclamide (5 mg/kg) was administered orally. [U-14C]-glucose (1·5× 
105 cpm) was injected intraperitoneally 2 h later and the expired CO2 was 
trapped in KOH containing vials and counted. 
b Not significantly different from a. 
c Significantly less than a Ρ <0·001. 
d Significantly greater than c P< 0·01. 
e Significantly greater than c P< 0·001. 
f Significantly greater than c P< 0·01. 
 
glucose and [l-14C]-palmitic acid. Oxidation of glucose which is impaired in 
diabetes is increased by insulin and lipoic acid and to a smaller extent by glibencla- 
mide. Oxidation of [l-14C]-palmitic acid which is increased in diabetes is reduced by 
insulin and lipoic acid and not by glibenclamide. Thus, the often small changes 
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Table 8. 14CO2 expiration from [l-l4C]-palmitic acid. 
 
 
Numbers in parentheses denote the number of animals. Lipoic acid (100 mg/kg) and 
insulin (40 i.u/kg) were administered intraperitoneally. Glibenclamide (5 mg/kg) was 
administered orally. 1-14C palmitic acid (l·5 × l05 cpm) was injected 
intraperitoneally two hours later and the expired CO2 was trapped in vials con-
taining KOH and counted. 
b Significantly greater than a P< 0·01. 
c Significantly less than b P < 0·01. 
d and c not significantly different from b 
 
obtained by substituting CoA with DTO add up to produce a substantial change in 
the overall homeostasis in diabetes. We believe that these effects are responsible for 
the beneficial effects of lipoic acid administration in diabetes. 
 
Metabolism of acetyl DTO 
 
While DTO can substitute for CoA in a wide array of enzymes involved in fatty acid 
oxidation and biosynthesis of fatty acids, triglycerides and phospholipids, it is 
interesting to note that acetyl DTO can also substitute for acetyl CoA in a number of 
enzymic reactions such as biosynthesis of malonyl DTO and HMG.DTO (vide 
supra), citrate synthesis, and participation in transacetylation reactions with thio-
esters of CoA (Brady and Stadman, 1954). 
As can be seen from table 9, acetyl DTO has about 40% of the specific activity of 
acetyl CoA for citrate synthase (Gandhi et al., 1985). 
It is not clear whether sufficient quantities of acetyl DTO are formed physio-
logically to warrant considerations of its oxidation through citric acid cycle. 
Nevertheless, it is important to note in this context that lipoic acid administration 
increases glucose oxidation. 
 
 
Table 9. Metabolism of acetyl DTO. 
 
Citrate synthase 
 
AcCoA (DTO) + OAA Citrate + CoA (DTO) 
 
 
*µ mol of thiol released/min/mg protein. 
The enzyme was isolated from normal rat liver 
mitochondria and partially purified. The enzyme was 
assayed by estimating the free thiol formed using 
DTNB. The product was identified as citrate. 
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DTO by a lipoyl transacetylase (EC 2·3·1·12) reaction can convert acetyl CoA to 
acetyl DTO. This enzyme is present in normal rat liver and has been partially 
purified. It was found that the enzyme had a specific activity of 0·4 n mol acetyl DTO 
formed/min/mg protein (Gandhi et al., 1985). 
 
 
Biosynthesis of lipoic acid 
 
 
The precursor for the biosynthesis of lipoic acid has been shown to be octanoic acid 
in Escherichia coli (White, 1980 a,b, 1981). Carreau et al. (1977) have shown that 
linoleic acid and to a smaller extent oleic acid act as precursors for lipoic acid bio-
synthesis in the rat. The reaction has been shown to occur predominantly in the 
microsomal fraction of rat liver (Spoto et al., 1982). We have found (table 11) that 
arachidonic acid appears to be the immediate precursor followed by linoleic acid for 
the biosynthesis of lipoic acid in normal and diabetic rats. Furthermore, in diabetic 
liver, biosynthesis of lipoic acid from linoleic acid is impaired and addition of insulin 
to the perfusion medium corrects this (table 12). It appears therefore, that in alloxan 
 
 
Table 10. Radioimmunoassay of serum insulin in normal and diabetic rats. 
 
 
d Significantly less than a p<0·05. 
c Significancy less than b Ρ < 0·02. 
Rats were sacrificed 1 h after intraperitoneal injection of lipoic acid at 
10 mg/100 g. Insulin levels were estimated using radioimmunoassay kit supp-
lied by Bhabha Atomic Research Centre, Bombay, following the procedure 
outlined therein.. 
 
Table 11.  Incorpation of 1-[14C]- labelled compounds into liver fat and lipoic acid. 
 
 
Livers were perfused with the labelled precursor for 1 h and incubated for 3 h at room temperature. Lipoic acid 
was isolated by extraction followed by TLC. The TLC fraction was further purified by HPLC. 
NE. Not estimated; ND, not detectable. 
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Table 12. Incorporation of l-[14C]-linoleic acid into lipoic acid in presence of 
insulin. 
 
ND, Not detectable. 
Livers were perfused with the labelled precursor for 1 h and incubated for 3 h at 
room temperature. In experiments with insulin, 0·25 i.u/ml of insulin was used in the 
perfusion medium. Lipoic acid was isolated and purified as described in table 11. 
 
 
 
diabetes, the biosynthesis of lipoic acid may be impaired, primarily due to the 
reduction in the conversion of linoleic to arachidonic acid (Brenner and Peluffo, 
1969). 
 
Does lipoic acid stimulate insulin secretion? 
 
Previous studies (Natraj et al., 1984) have shown that lipoic acid administration at 
10mg/l00 g in alloxan diabetic rats resulted in beneficiation of the following 
biochemical lesions: 
 
– Serum pyruvate normalised in 1 h. 
– Liver pyruvate dehydrogenase normalised in l h. 
– Blood sugar reduced by 40% in 4 h. 
– Serum acetoacetate decreased by a 3 fold margin in 24 h. 
– Liver glycogen increased by a 2 fold margin in 24 h. 
– Liver fatty acid synthesis increased by a 2 fold margin in 24 h. 
 
These are similar to the effect of insulin administration. Lipoic acid on reduction 
forms DTO which has two sulphydryl groups and sulphydryl containing compounds 
in vitro have been shown to stimulate insulin secretion (Haugaard and Haugaard, 
1970; Lavis and Williams, 1970). Hence there is always the question whether the 
beneficial effects observed due to administration of lipoic acid are really due to lipoic 
acid per se or intermediated through insulin response. Table 10 shows that insulin 
levels in diabetes or in the normal state is uninfluenced by the administration of 
lipoic acid indicating that the effect of lipoic acid is specific and not mediated 
through insulin. 
 
 
An overview of research on lipoic acid and diabetes 
 
In figure 4, we have given a list of reactions where DTO substitutes for CoA 
completely or partially. These are acetate, acetoacetate, succinate, malonate and fatty 
acid activation; HMG, citrate and fatty acid synthesis, glyceride and phospholipids 
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Figure 4. Comparison of DTO and CoA. 
 
 
biosynthesis and pyruvate oxidation. In many of the reactions where DTO replaces 
CoA the rates of the reaction are of the order of 50% of CoA. 
Figure 5 indicates reactions where DTO does not substitute for CoA. These are 
thiolase, thiophorase and pyruvate carboxylase reactions. The non-participation of 
DTO in these 3 reactions is purposeful in reduction of ketogenesis and 
gluconeogenesis. 
 
 
Figure 5. Comparison of CoA and DTO. 
 
 
As can be seen from the results described so far, most enzymatic reactions 
involving DTO or acetyl DTO are less active as compared to CoA or acetyl CoA. 
One reason for this could be that the DTO used was a racemic mixture and the 
acetyl DTO is a mixture of 4 possible isomers (+) and (–) 6-S-acetyl and (+) and 
(–) 8-S-acetyl derivatives. If only one of these derivatives is the actual substrate for 
the enzymatic reactions, then the actual concentration of active acetyl DTO would 
be a fourth of the applied concentration. This indeed, was found to be the case for 
citrate synthase wherein, the Km for acetyl DTO was 4 times higher than for acetyl 
CoA (Wagh et al., 1986). It has been reported that acylation of the lipoic acid 
residues in the enzyme complex of pyruvate dehydrogenase is asymmetric with the 8- 
S-acetyl derivative being the first product (O'Connor et al., 1982). 
Research on lipoic acid originated from experiments with alloxan diabetic rats and 
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progressed to studies with isolated enzymes ending up with the enunciation of novel 
pathways for the biosynthesis of fatty acids, triglycerides and phospholipids. 
Although, the effects of lipoid acid have been demonstrated in diabetic animals as a 
model system, the significance of these findings transcends the confines of this disease 
state and are relevant to the normal animal as well. The results obtained with 
triglyceride and phospholipid biosynthesis where fatty acyl DTO is in fact a better 
substrate than fatty acyl CoA merits special attention, since it raises the question as 
to whether in the normal animal activation of fatty acids for triglyceride and pho-
spholipid biosynthesis occurs with the help of thiols other than CoA. It may be 
recalled that in the oxidation of fatty acids the requirement for CoA as the thiol 
component appears to be absolute. It is in keeping with nature's way of controlling 
and differentiating metabolic fluxes, to propose that CoA thioesters of fatty acids are 
primarily utilized for oxidation and DTO thiesters for lipid biosynthesis. 
The role of essential fatty acids in various biochemical processes such as 
precursors for thromboxanes, prostaglandins etc. and as integral components of 
phospholipids in the membranes where, by virtue of their lower melting temperatures 
they confer a higher degree of fluidity to the membrane has been well established. It 
has also been shown (Houtsmuller et al., 1981) that essential fatty acids have an 
insulin sparing action in diabetes. The mechanism of this however is not clear. It is 
possible that increased fluidity of membranes may influence membrane processes 
such as transport, hormone receptor interaction, signal transduction etc. which 
individually or collectively may be responsible for the observed effects of essential 
fatty acids in diabetes. An even more intriguing angle to this is the conversion of 
essential fatty acids and particularly arachidonic acid to lipoid acid (Menon and 
Natraj, 1984). The fact that arachidonic acid levels are reduced in diabetes and that 
linoleic acid to arachidonic acid conversion is insulin dependent raises the question 
whether a part of the problem in diabetes is due to the reduced formation of lipoic 
acid. 
In summary, the role of lipoic acid in intermediary metabolism may not be 
confined to its cofactor role in α-keto acid dehydrogenases but may Dell extend to 
certain reactions especially in lipid biosynthesis where, it may replace CoA for 
activating fatty acids prior to acylation with L-glycerol-3 phosphate. The significance 
of these reactions will become clearer if lipoic acid can sustain growth of pantho-
theine requiring mutants in the absence of panthotheine. 
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